Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559173 | 1.00 | IKBKB (1.00) | IKBKBCHUK | |
| SCHEMBL3464191 | 1.00 | IKBKB (1.00) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4500337 | 0.99 | IKBKB (0.98) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4514515 | 0.99 | IKBKB (0.98) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4509040 | 0.99 | IKBKB (0.98) | IKBKBCHUK | |
| SCHEMBL4614268 | 0.90 | IKBKB (0.82) | IKBKBCHUK | |
| SCHEMBL4613934 | 0.90 | IKBKB (0.81) | IKBKB | |
| Hydrochloric Acid SCHEMBL30341853 | 0.90 | IKBKB (0.81) | IKBKBCHUK | |
| SCHEMBL4612399 | 0.89 | IKBKB (0.80) | IKBKBCHUK | |
| SCHEMBL14028520 | 0.88 | IKBKB (0.78) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912646-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | Bayer HealthCare AG (DE) | 2008-04-23 | — | — | EP | claimed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2007014671-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-02-08 | — | — | WO | claimed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | claimed |
| US-9173920-B2 | Methods of treating muscular wasting diseases using NF-KB activation inhibitors | THERALOGICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173920-B2 | Methods of treating muscular wasting diseases using NF-KB activation inhibitors | THERALOGICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8426355-B2 | Methods of treating muscular wasting diseases using NF-κB activation inhibitors | THERALOGICS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426355-B2 | Methods of treating muscular wasting diseases using NF-κB activation inhibitors | THERALOGICS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | disclosed |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | disclosed |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| EP-1487842-B1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007014671-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | BAYER HEALTHCARE AG (DE) | 2005-09-29 | — | — | US | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | IKBKB 1024/4885CHUK 372/4885 |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | IL1B, NFKBIA, IL17A | IKBKB 28/4885CHUK 17/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | IKBKB 2996/4885CHUK 996/4885 |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | IL1B, NFKBIA, IL1A | IKBKB 25/4885CHUK 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.